Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
NCT05404945Phase 2Active, not recruiting
- Sponsor
- University of Virginia
- Start
- Jul 2022
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in classical Hodgkin lymphoma (cHL) (3 cohorts), sponsored by University of Virginia. Primary endpoints: Complete Remission Rate at 2 years and Incidence of grade 3-5 treatment-related AEs at 2 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05404945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404945.